Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice

Frontiers in Cardiovascular Medicine

Sophie Van Linthout¹  Kathleen Pappritz¹  Carsten Tschöpe²  Muhammad El-Shafeey³  Bahtiyar Kerim⁴  Fengquan Dong⁴  Kapka Miteva⁵  Arpad Kovacs⁶  Nazha Hamdani⁷  Lisa O'Flynn⁸  Stephen Joseph Elliman⁸  Timothy O'Brien⁹ 

[1] Berlin Institute of Health at Charité – Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany;Berlin-Brandenburg Center for Regenerative Therapies, Charité, Universitätsmedizin Berlin, Berlin, Germany;German Center for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany;Berlin Institute of Health at Charité – Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany;Berlin-Brandenburg Center for Regenerative Therapies, Charité, Universitätsmedizin Berlin, Berlin, Germany;German Center for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany;Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany;Berlin Institute of Health at Charité – Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany;Berlin-Brandenburg Center for Regenerative Therapies, Charité, Universitätsmedizin Berlin, Berlin, Germany;German Center for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany;Medical Biotechnology Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications, Alexandria, Egypt;Berlin-Brandenburg Center for Regenerative Therapies, Charité, Universitätsmedizin Berlin, Berlin, Germany;Berlin-Brandenburg Center for Regenerative Therapies, Charité, Universitätsmedizin Berlin, Berlin, Germany;Division of Cardiology, Foundation for Medical Research, Department of Medicine Specialized Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland;Institute of Physiology, Ruhr University Bochum, Bochum, Germany;Institute of Physiology, Ruhr University Bochum, Bochum, Germany;Molecular and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany;Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany;Orbsen Therapeutics, National University of Ireland Galway, Galway, Ireland;Regenerative Medicine Institute and Department of Medicine, National University of Ireland Galway, Galway, Ireland;

关键词: type 2 diabetes;    diabetic cardiomyopathy;    syndecan-2/CD362-selected stromal cells;    immunomodulation;    cardiomyocyte stiffness;    cardiac fibrosis;    angiogenesis;   

DOI  :  10.3389/fcvm.2021.632728

来源: Frontiers

【 授权许可】

CC BY